Abbisko Cayman Limited (02256.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−5.3x

Market Cap

HKD 5.48B

MomentumView details →

1D Return

−1.79%

YTD Return

−32.63%

RSI (14)

32.1

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−5.3x

Market Cap

HKD 5.48B

RSI (14)

32.1

MomentumView details →

1D Return

−1.79%

YTD Return

−32.63%

ProfitabilityView details →

Gross Margin

98.19%

Net Margin

−479.81%

EBITDA Margin

−523.46%

ROE (TTM)

−21.41%

ROA (TTM)

−17.31%

Asset Turnover

0.04x

GrowthView details →

Revenue YoY

−84.28%

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

+459.32%

EPS CAGR 3Y

+115.25%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

−HKD 0.35

EPS Surprise

11.76%

Beats (12Q)

1/12

Next Q EPS Est

−HKD 0.49

Avg Surprise (4Q)

11.76%

Rev Surprise

94.35%

Capital & dividendView details →

Debt/Equity

0.21x

Current Ratio

4.82x

Quick Ratio

4.82x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

97.27M

Net Income (TTM)

−466.69M

Op. CF (TTM)

−224.05M

Next earningsMar 18, 2027 →

Latest newsMore news →

Abbisko Therapeutics reported an interim net loss of 193 million RMB for the six months ended June 2026, swinging from a profit of 328 million RMB a year earlier, with revenue down 84.1% to 97.27 million RMB.11d ago

Abbisko Therapeutics entered into a strategic research collaboration and license agreement with Eli Lilly.73d ago

Similar companies

CRISPR Therapeutics AGCRSP Erasca, Inc.ERAS Apellis Pharmaceuticals, Inc.APLS 博拓生物688767.SH Ligand Pharmaceuticals IncorporatedLGND CK Life Sciences Int'l., (Holdings) Inc.00775.HK Find similar companies →

Latest newsMore news →

Abbisko Therapeutics reported an interim net loss of 193 million RMB for the six months ended June 2026, swinging from a profit of 328 million RMB a year earlier, with revenue down 84.1% to 97.27 million RMB.11d ago Abbisko Therapeutics entered into a strategic research collaboration and license agreement with Eli Lilly.73d ago